TuHURA BIOSCIENCES, INC./NV Deferred Tax Assets, Net of Valuation Allowance
TuHURA BIOSCIENCES, INC./NV (HURA) had Deferred Tax Assets, Net of Valuation Allowance of $2.66 million as of 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2026-03-31
- 2025-12-31: Deferred Tax Assets, Net of Valuation Allowance $2.66M.
- 2024-12-31: Deferred Tax Assets, Net of Valuation Allowance $51.17K.
- 2023-12-31: Deferred Tax Assets, Net of Valuation Allowance $65.45K.
| Period end | Deferred Tax Assets, Net of Valuation Allowance |
|---|---|
| 2025-12-31 | $2.66M 10-K · filed 2026-03-31 |
| 2024-12-31 | $51.17K 10-K · filed 2026-03-31 |
| 2023-12-31 | $65.45K 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |